Conflict of interest statement: Competing interests: None declared.79. Cancer Discov. 2018 Jun;8(6):OF14. doi: 10.1158/2159-8290.CD-RW2018-071. Epub2018 Apr 27.Everolimus Enhances the Efficacy of Fulvestrant in ER+ Breast Cancer.[No authors listed]mTOR inhibition with everolimus extends progression-free survival in combination with fulvestrant.Â©2018 American Association for Cancer Research.DOI: 10.1158/2159-8290.CD-RW2018-071 PMID: 29703823 